In women with severe osteoporosis, teriparatide versus risedronate risk reduction did not significantly differ across analyzed subgroups for most fracture endpoints.
In plain wordsIn women with severe osteoporosis, most fracture risk reductions with teriparatide versus risedronate did not differ significantly across subgroups.
- Peptide
- Teriparatide (PTH 1-34)
- Outcome
- No significant changeFracture treatment-effect heterogeneity across subgroups
- Study
n = 1,360
- Comparator
- Risedronate
- Outcome group
- Bone and joint · Musculoskeletal
Measurements
- Treatment-by-subgroup interaction p
- > 0.1
- most fracture endpoints
Source sentences
For most fracture endpoints, the risk reduction of teriparatide versus risedronate did not significantly differ in any of the subgroups analyzed (treatment-by-subgroup interaction p > 0.1), with most subgroups mirroring results from the total study population.
2 context sentences(design, population, supporting numbers)
The 2-year, randomized, double-blind, active-controlled fracture endpoint VERO study included postmenopausal women with established osteoporosis, who had at least 2 moderate or 1 severe baseline vertebral fractures (VFx), and bone mineral density (BMD) T-score ≤-1.5.
Patients were treated with either s.c. daily teriparatide 20 μg or oral weekly risedronate 35 mg.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).